Miriam Düll

Clinician Scientist, passionate about connecting science and patient care in #hepatology, with a focus on symptoms of #itch, #pain and #neuropathy

[Miriam Düll @duell_miriam]

Excited for our session on sensory nerve fibers tomorrow, April 29, 9.30 am!
@BritishNeuro @physoc

[ERN RARE LIVER @ERN_RARE_LIVER]

Afternoon at #Academy2025:

🔬 Expert talk by Christoph Schramm on Primary Biliary Cholangitis

👥 Split into 3 groups for expert-led case discussions

🎤 Wrapped up with insightful presentations
Great to see such teamwork & learning in action! 💡

#RareLiver #ERN #LiverDisease

[ERN RARE LIVER @ERN_RARE_LIVER]

🎉 The 2025 ACADEMY is on in Heidelberg!

Kicked off with welcomes from Uta Merle, Patrick Michl & Peter Schirmacher, plus an intro to ERN RARE-LIVER by Hendrik Matthies.

Talks by Joost Drenth & Michael Trauner opened the floor, & 20 young clinicians from 13 countries are here!

[EASLnews @EASLnews]

🌷 Happening on 7-10 May in Amsterdam, the Netherlands, and online!

🗓️The scientific programme for #EASLCongress is now live! Consult the details and start planning your experience with a comprehensive lineup of sessions designed to cover every aspect of hepatology.

🤩Each corner of RAI Amsterdam will be buzzing with the latest advancements and delegates attending from all over the world. Don’t miss out!

Check the programme: https://t.co/lyWzLrbYqA
Submit your abstract by 3 December: https://t.co/UFUaiPvbPL
Register with early fees by 14 January: https://t.co/pRbCXwnZ2x

@EASLedu @AleksanderKrag @DebbieShawcros1 @RuiCastroHD @fprusso73 @bogdanprocopet @SagiZelber @analleo @SaSi_Lens

[Journal of Crohn's and Colitis @JCC_IBD]

Integrin αVß6 - autoantigen and driver of epithelial remodeling in colon and bile ducts in #PSC and #IBD. Roth et al. https://t.co/fPqO0NLLBR

[Miriam Düll @duell_miriam]

Out now, our paper in @JCC_IBD Integrin αVß6 - autoantigen and driver of epithelial remodeling in colon and bile ducts in #PSC and #IBD

https://t.co/AfGGhUbyxq

[Journal of Hepatology @JHepatology]

🆕EASL #CPGs on the management of MASLD❗️

✅Update on definitions, prevention, screening, diagnosis & treatment for #MASLD

Full text👉https://t.co/DfkYMNEX29

✴️Joint publication with EASD & EASO❕

@EASLnews
@EASLedu
@AleksanderKrag
@DebbieShawcros1

[Arndt Vogel @ArndtVogel]

🔥news from #EASL2024
Liver transplantation following HCC downstaging with atezolizumab/bevacizumab: preliminary results of the ImmunoXXL study
👏still early, but amazing data
👉ICI before LTx seems feasible & safe
🧐Real chance to improve outcome in HCC
@EASLedu @myESMO @ILCAnews #livertwitter

[EASLnews @EASLnews]

Awareness on how to keep our liver healthy should start as early as possible! 🧑‍🎓

🏫The #LoveYourLiver impact projects have already kicked off in schools across Italy, ahead of #EASLCongress 2024.

Teaming up with @UniPadova and Project 2023 Third Mission, hepatologists are visiting classrooms and educating young pupils on the importance of liver care. ⭐️

On 3 June, the project will roll out in Milan, our #EASLCongress host city, leaving a lasting legacy on our future generation!

"Prevention is a key factor for liver health: by making the right choices every day we can protect our liver, and also influence our overall wellbeing." - @fprusso73

Watch the video from our school visit in Padova!

[EASLnews @EASLnews]

The prevalence of Steatotic Liver Disease is staggering, affecting millions worldwide, and linked to t2 diabetes and obesity.

Collaboration is key in the fight against SLD. Through partnerships with health leaders, policymakers, and patient organisations, we're fostering a united front.
Together, let's make SLD visible on the global health agenda.

By uniting our efforts and advocating for change on occasions such as #WorldLiverDay, we can pave the way for healthier livers and healthier lives.

Read more: https://t.co/jVonB1OBDM

@WorldLiverDay

[EASLnews @EASLnews]

After over 20 years of dedicated research and drug development, the FDA has granted approval for the first anti-MASH drug. This marks a pivotal moment for patients battling MASH, whose quality of life and long-term prognosis have been greatly affected by this challenging disease.

For those where lifestyle modifications alone aren't enough, there is now hope with the availability of Resmetirom.

Resmetirom has been licensed for patients with non-cirrhotic MASH and liver fibrosis, providing a much-needed treatment option for those with significant or advanced fibrosis. It is important to note that alongside this medication, diet and exercise remain fundamental pillars of management, as emphasised by the FDA.

EASL eagerly anticipates the global availability of this treatment and is optimistic that this milestone will spur the development of further drugs to combat MASH.

While this approval is a significant victory, there's still work to be done, particularly for patients with cirrhosis who currently lack approved drug treatment options.

#livertwitter

[PSC Support @PSCSupportUK]

On #WorldPSCDay we want to flood the internet with #PSCinformation. #PSC is a rare & often misunderstood disease. Let's raise the volume and encourage more conversations. Share your story and our posts to spread the word. 💬#GlobalPSCAwareness #PSCAwareness #RareDiseaseAwareness

[Elliot Tapper @ebtapper]

MAESTRO-NASH is a positive trial

Resmetirom improved NASH resolution and reduced fibrosis at 52-weeks. It is safe.

Is it a landmark study? Yes
Will it change NASH? Depends on cost, adherence in real world, and effect on clinical outcomes #EASLCongress #LiverTwitter

[massimo iavarone @massimoiava]

CAMARO open label RCT study for #autoimmune hepatitis
1. #mycophenolate vs #azatioprine
2. 31 vs 39 pts
3. ✅️ Primary outcome: % clinical remission reached: 55% vs 29%
4.🟰 cumulative dose of #prednisolone
5. NO severe adverse events in MMF arm
6. 🟰 in QoL
#EASLCongress

[Journal of Hepatology @JHepatology]

📢NEW

@EASLnews Clinical Practice Guidelines on acute-on-chronic liver failure

Available here:
https://t.co/GCNg1AIX9X

[Miriam Düll @duell_miriam]

An amazing time at #EASLCongress! Great scientific and clinical program, met many collagues and enjoyed Vienna! #LiverTwitter

[Dr.Bornie @Apichatka]

The new name of #NAFLD 😇

🗣️ MASLD
🍺🍩 MetALD
🍺 ALD
👤 specific etiology SLD
🧩 cryptogenic SLD

#EASLCongress #LiverTwitter @EASLnews @EASLedu @AASLDtweets

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Decision to use a single criteria to improve sensitivity #EASLCongress

[Jeffrey V. Lazarus @JVLazarus]

@EASLnews Dr Arun Sanyal presenting the NAFLD nomenclature change.
Read about it here in @JHepatology
https://t.co/0VVwz6vRau
and @HEP_Journal https://t.co/0sv7sOVz2z
@AASLDtweets @alehlatam